SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is surging amidst escalating Middle East tensions and concerns over restricted oil flows through the Strait of Hormuz, sparking community speculation on a prolonged energy shock versus an eventual price correction.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending amidst an intense community debate surrounding the Trump administration's "war with Iran," with proponents celebrating decisive actions against a perceived terrorist threat, while detractors highlight escalating global tensions, rising gas prices, and alleged distractions from other controversial matters.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is trending amid discussions of its recent integration with Coinbase's DEX, with the community highlighting its multi-chain presence across Solana, Base, and Cronos, alongside an active burning mechanism and a strong organic following.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is gaining traction as escalating conflict in the Middle East, marked by attacks on key oil infrastructure and disruptions in the Strait of Hormuz, fuels community concern over potential prolonged supply shortages and a significant rally in crude oil prices.

ProShares Trust - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is seeing intense discussion and price action driven by escalating geopolitical tensions in the Middle East, particularly concerning Iran and the critical Strait of Hormuz. The community is actively speculating on potential crude oil supply disruptions, with many anticipating a significant rally for oil prices.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

The upcoming March 12 Investor Day is driving significant conversation for Lucid, as investors eagerly await details on its new mid-size EV platform and potential partnerships, sparking hopes for a short squeeze given high short interest. However, community sentiment remains deeply divided following mixed earnings that showed strong revenue growth but wider losses and a recent workforce reduction, leading to ongoing concerns about cash burn and future dilution.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending amid escalating Middle East tensions and concerns over global stability, yet community discussions reflect a mix of expectations for gold's safe-haven appeal and frustration over its recent downturn attributed to a strong US Dollar and alleged market manipulation.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as community excitement builds around recent statements from its CEO, hinting at the potential for "curative outcomes" from its GPS immunotherapy. Investors are closely watching for updates from the Miami Cancer Institute Summit and anticipating the delayed Phase 3 REGAL trial results, widely believed to signal significant efficacy and potential for a major pharma buyout.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is a central discussion point amid escalating Middle East geopolitical tensions, with the effective closure of the Strait of Hormuz and attacks on regional oil and LNG facilities causing crude prices to surge. The community is actively debating whether the stock's current movement fully reflects the magnitude of this supply disruption, with many seeing XOM as a critical hedge in a rapidly shifting global energy landscape.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as its utility gains traction through major integrations with Sui and Cardano, alongside a notable partnership with the US Commerce Department to publish economic data on-chain. The community is buzzing about its position as a vital Real World Asset (RWA) oracle, often comparing its fundamental value against meme tokens, further fueled by its newly announced token buyback program.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Citi kept a ‘Neutral’ rating on Moderna with a $41 price target.</li><li>BofA contends that Moderna's settlement takes "a meaningful chunk of the litigation overhang off the table," but adds that the agreement is "also not the walk-away outcome we expect some bulls were hoping for."&nbsp;</li><li>Under the settlement, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026.</li></ul>Shares of vaccine maker Moderna (MRNA) rallied 16% on Wednesday after the company announced that it has entered into an up to $2.25 billion settlement with Genevant Sciences and Arbutus Biopharma over a vaccine patent row which has left analysts divided.Under the <a href="https://stocktwits.com/news-articles/markets/equity/mrna-shares-rally-after-hours-on-settlement-deal-over-vaccine-patent-row/cZderPnRIPy">settlement</a>, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026. The remaining $1.3 billion is subject to further litigation, the company said on Tuesday. If Moderna prevails in the litigation, no further payments will be due but if it doesn't, it will have to make an additional payment of up to $1.3 billion.<h2 class="st-heading-2">Analyst Take</h2>Citi analyst Geoff Meacham views Moderna's settlement with Arbutus as not the best-case scenario of an outright win but better than feared. The news is likely to come as a relief to many investors, the analyst told investors in a research note, while adding that it thinks the settlement removes an overhang for the stock. Citi kept a ‘Neutral’ rating on Moderna with a $41 price target.BofA, likewise, contends that Moderna's settlement takes "a meaningful chunk of the litigation overhang off the table," but adds that the agreement is "also not the walk-away outcome we expect some bulls were hoping for."The structure leaves "a contingent tail" as Moderna could owe an additional payment of up to $1.3 billion if further litigation affirms liability, noted the analyst, who reiterated an ‘Underperform’ rating and $31 price target on Moderna shares.<h2 class="st-heading-2">Settlement Deal</h2>The settlement announced on Tuesday resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ Lipid Nanoparticle (LNP) delivery technology in its COVID-19 vaccine Spikevax as well as respiratory syncytial virus (RSV) vaccine mRESVIA. The company said that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRNA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> have gained nearly 90% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/farm-stock-sinks-to-48-year-lows-what-triggered-the-collapse/cZd9tBARId3">FARM Stock Sinks To 48-Year Lows – What Triggered The Collapse?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock

The news is likely to come as a relief to many investors, Citi told investors in a research note. 

Equity

The news is likely to come as a relief to many investors, Citi told investors in a research note. 


Arbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading Volume - What's Next?

Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading Volume - Still a Buy...

MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS

Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ending global litigation.

Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus

(RTTNews) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary of Roivant...

<ul class="summary-bullets"><li>Moderna said that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.&nbsp;</li><li>Under the deal, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026.</li><li>The remaining $1.3 billion payout is subject to further litigation.</li></ul>Shares of vaccine maker Moderna (MRNA) rallied after hours on Tuesday after the company announced that it has entered into an up to $2.25 billion settlement with Genevant Sciences and Arbutus Biopharma.The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ Lipid Nanoparticle (LNP) delivery technology in its COVID-19 vaccine Spikevax as well as respiratory syncytial virus (RSV) vaccine mRESVIA. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5178901572623640&amp;symbol=MRNA">said</a> that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.<a href="https://stocktwits.com/symbol/ABUS">Shares of Arbutus</a> fell 8% after hours at the time of writing while shares of Genevant’s parent <a href="https://stocktwits.com/symbol/ROIV">Roivant Sciences</a> gained nearly 1%. Meanwhile, shares of MRNA rallied 11%.<h2 class="st-heading-2">Settlement Agreement</h2>Under the deal, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026. The remaining $1.3 billion is subject to further litigation. If Moderna prevails in the litigation, no further payments will be due but if it doesn't, it will have to make an additional payment of up to $1.3 billion."Resolving this legacy matter from our pandemic response removes uncertainty and allows us to turn our full focus to Moderna's exciting near-term future," said Moderna CEO Stéphane Bancel.The company now expects to end the year with $4.5 to $5.0 billion in cash and cash equivalents. The total projected liquidity available to the company at the end of 2026 will be $5.4 to $5.9 billion, it added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRNA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> have gained nearly 65% over the past 12 months. Meanwhile, ABUS and ROIV added 37% and 174%, respectively.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/autozone-shares-dive-post-earnings-but-wells-fargo-sees-buying-opportunity/cZdeYkuRIPt">AutoZone Shares Dive Post-Earnings But Wells Fargo Sees A Buying Opportunity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration vials of vaccines for coronavirus (COVID-19). Vaccines from left to right, Moderna, Bimervax, Comirnaty and Pfizer BioNTech. (Photo Illustration by Marcos del Mazo/LightRocket via Getty Images)

MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccine Spikevax.

Western Standard LLC Makes New $2.31 Million Investment in Arbutus Biopharma Corporation $ABUS

Western Standard LLC bought a new position in Arbutus Biopharma Corporation (NASDAQ:ABUS - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought...

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving Average - Here's What Happened

Arbutus Biopharma (NASDAQ:ABUS) Shares Pass Above 200-Day Moving Average - Should You Sell...

Moderna faces $5 billion mRNA patent lawsuit after 'Star Trek' ruling

Behind the household COVID-19 name, Moderna, is facing a $5 billion patent-infringement lawsuit over vaccine technology.On February 2, 2026, U.S. District Judge Joshua D. Wolson denied Moderna's...

Traders Buy Large Volume of Call Options on Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma Corporation (NASDAQ:ABUS - Get Free Report) saw some unusual options trading activity on Tuesday. Stock investors purchased 5,605 call options on the stock. This is an increase of...

<ul class="summary-bullets"><li>The verbal ruling was delivered on January 15, without written reasons, the company said.</li><li>The company said it disagrees with the outcome and plans to seek a review by the Enlarged Board of Appeal once the written ruling is issued.</li><li>The company does not expect the ruling to impact outcomes of its patent infringement cases against Moderna.</li></ul>Arbutus Biopharma Corp. (ABUS) stock crashed more than 18% on Friday after the European Patent Office (EPO) revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.This marked the <a href="https://stocktwits.com/symbol/ABUS">ABUS stock’s</a> biggest intraday decline since July 2020.The verbal ruling was delivered on January 15 without written reasons, Arbutus said. The EPO ruling reverses two earlier decisions that had upheld an amended version of the patent EP 2279254. According to Google Patents, it covers “Novel lipid formulations for nucleic acid delivery.”The company said it disagrees with the outcome and plans to seek a review by the Enlarged Board of Appeal once the written ruling is issued. Arbutus acknowledged that the decision could affect certain European legal actions against Moderna, including a case in Switzerland and a proceeding before the Unified Patent Court in which the patent is being asserted.<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> (MRNA) jumped 7%, while <a href="https://stocktwits.com/symbol/MRK">Merck</a> (MRK) traded 2% lower.<h2 class="st-heading-2">Impact Outside Europe</h2>Arbutus stressed that the revocation was based on the EPO’s “added matter” standard, which does not apply in other jurisdictions.As a result, the company does not expect the ruling to impact the timing or potential outcomes of its patent infringement cases against Moderna in the United States, Japan, or Canada, a separate Unified Patent Court case not involving the patent, or its ongoing litigation against Pfizer and BioNTech in the U.S.<h2 class="st-heading-2">Retail Reaction</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/ABUS_jpg_f665738876.webp" alt="ABUS.jpg">One user sees the drop as an opportunity to take up fresh positions.<stembedurl>https://stocktwits.com/LS172/message/642060814</stembedurl>One user said it’s all noise and nothing has changed ‘other than the bad headline’.<stembedurl>https://stocktwits.com/EdDwg/message/642040053</stembedurl>The stock has gained around 20% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-jfbr-stock-surge-today/cmUlvsnR4B0">Why This Penny Stock Is On Track To Gain For First Time In 10 Sessions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Plug Power said it was impacted by the speed and development of hydrogen economy.

ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe?

The European Patent Office revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

ABUS
Arbutus Biopharma Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABUS News

ABUSArbutus Biopharma Corp